RxDoctor Payments Data

Walter Carnahan, DO

Family Medicine · Southaven, MSNPI 1174501449

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $104,278 of the $145,716 with a category attached, or 71.6%. 9 manufacturers reported payments, led by AbbVie at 34.7% of the total. Reporting peaked in 2021 at $48,818 and has fallen 87.6% since, to $6,046 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$145,716in general payments, 2019–2025

Across 248 payments — averaging $587.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$51K
  • Lilly USA, LLC$32K
  • Teva Pharmaceuticals USA, Inc.$25K
  • Biohaven Pharmaceuticals, Inc.$15K
  • Amgen$13K
  • Impel Pharmaceuticals Inc.$5K
  • plus $5K from 3 others

What the payments were for

  • Consulting fees$25,69318%
  • Speaking & faculty fees$104,27872%
  • Grants$420%
  • Travel & lodging$9,8477%
  • Food & beverage$5,7984%
  • Education$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,716 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$82,079
Medicare patients
306
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$38,500
JanuviaSitagliptin Phosphate30$36,701
Aimovig AutoinjectorErenumab-Aooe39$29,998
EliquisApixaban30$28,483
Emgality PenGalcanezumab-Gnlm31$24,746
JardianceEmpagliflozin20$23,075
RybelsusSemaglutide14$20,672
MounjaroTirzepatide17$17,481
UbrelvyUbrogepant14$15,121
XareltoRivaroxaban11$9,650
Dexlansoprazole DrDexlansoprazole13$6,515
SynthroidLevothyroxine Sodium51$5,996
Ezetimibe156$4,447
SymbicortBudesonide/Formoterol Fumarate17$3,857
Fenofibrate110$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$28,48330 claims
AbbVieUbrelvy, Synthroid$50,582$21,11765 claims
Lilly USA, LLCMounjaro$31,855$17,48117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →